Search

Your search keyword '"Tumor Suppressor Protein p53 antagonists & inhibitors"' showing total 1,447 results

Search Constraints

Start Over You searched for: Descriptor "Tumor Suppressor Protein p53 antagonists & inhibitors" Remove constraint Descriptor: "Tumor Suppressor Protein p53 antagonists & inhibitors"
1,447 results on '"Tumor Suppressor Protein p53 antagonists & inhibitors"'

Search Results

201. Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2.

202. p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling.

203. p53 inhibition by MDM2 in human pterygium.

204. Hazardous impacts of silver nanoparticles on mouse oocyte maturation and fertilization and fetal development through induction of apoptotic processes.

205. Inhibiting mechanism of small molecule toward the p53-MDM2 interaction: A molecular dynamic exploration.

206. Role of p53 and transcription-independent p53-induced apoptosis in shear-stimulated megakaryocytic maturation, particle generation, and platelet biogenesis.

207. Design, synthesis and pharmacological evaluation of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives as potential antitumor agents.

208. High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma.

209. Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors.

210. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.

211. Inhibiting aberrant p53-PUMA feedback loop activation attenuates ischaemia reperfusion-induced neuroapoptosis and neuroinflammation in rats by downregulating caspase 3 and the NF-κB cytokine pathway.

212. Fluctuations in p53 Signaling Allow Escape from Cell-Cycle Arrest.

213. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.

214. MDM2 controls NRF2 antioxidant activity in prevention of diabetic kidney disease.

215. The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.

216. Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells.

217. LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53.

218. Wuho/WDR4 deficiency inhibits cell proliferation and induces apoptosis via DNA damage in mouse embryonic fibroblasts.

219. Does p53 Inhibition Suppress Myocardial Ischemia-Reperfusion Injury?

220. Adenovirus 5 E1A-Mediated Suppression of p53 via FUBP1.

221. Exposure of human melanocytes to UVB twice and subsequent incubation leads to cellular senescence and senescence-associated pigmentation through the prolonged p53 expression.

222. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

223. Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.

224. Total Synthesis and Biological Evaluation of Siladenoserinol A and its Analogues.

225. P53 Promotes Retinoid Acid-induced Smooth Muscle Cell Differentiation by Targeting Myocardin.

226. MicroRNA-138 Inhibits Cell Growth, Invasion, and EMT of Non-Small Cell Lung Cancer via SOX4/p53 Feedback Loop.

227. TP53 in adult acute lymphoblastic leukemia.

228. Synthesis and biological evaluation of naphthalimide-polyamine conjugates modified by alkylation as anticancer agents through p53 pathway.

229. H19 promotes the proliferation of osteocytes by inhibiting p53 during fracture healing.

230. The receptor for advanced glycation end products: A fuel to pancreatic cancer.

231. SRT2104 attenuates diabetes-induced aortic endothelial dysfunction via inhibition of P53.

232. Low-level overexpression of p53 promotes warfarin-induced calcification of porcine aortic valve interstitial cells by activating Slug gene transcription.

233. MicroRNA-188-3p is involved in sevoflurane anesthesia-induced neuroapoptosis by targeting MDM2.

234. SRC Increases MYC mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function.

235. Neuroprotection with the P53-Inhibitor Pifithrin-μ after Cardiac Arrest in a Rodent Model.

236. Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.

237. Long non-coding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) promote cell proliferation in colorectal cancer by affecting P53.

238. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

239. Targeting mutant p53 for efficient cancer therapy.

240. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity.

241. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters.

242. ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.

243. Crosstalk Between Nuclear Glucose-Regulated Protein 78 and Tumor Protein 53 Contributes to the Lipopolysaccharide Aggravated Apoptosis of Endoplasmic Reticulum Stress-Responsive Porcine Intestinal Epithelial Cells.

244. The Impact of Preexisting Chronic Kidney Disease on the Severity and Recovery of Acute Kidney Injury.

245. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.

246. Polyphyllin I Induces Cell Cycle Arrest and Cell Apoptosis in Human Retinoblastoma Y-79 Cells through Targeting p53.

247. MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts.

248. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.

249. Diagnostics of Early Changes in the Immune System Due to Low Concentration of N-Nitrosamines in the Blood.

250. NR4A1 Promotes Diabetic Nephropathy by Activating Mff-Mediated Mitochondrial Fission and Suppressing Parkin-Mediated Mitophagy.

Catalog

Books, media, physical & digital resources